PRYP4

Across TCGA pan-cancer cohorts, PRYP4 RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated PRYP4 data layer.

The strongest signal is observed in pheochromocytoma and paraganglioma (PCPG), where higher PRYP4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRYP4 expression acts as an unfavorable survival marker.

PCPG are the cancer types where PRYP4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PCPG	DFS	Tertile	All	0.070	0.936	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

PRYP4–PCPG (DFS)

Open the PCPG breakdown →